Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing.
The post Ultragenyx Crashes, On Deck To Hit A Record Low, On A Shocking Failure appeared first on Investor's Business Daily.
